… A phase 3 clinical trial compared erlotinib alone with erlotinib plus bevacizumab in patients
who had disease progression after platinum-based therapy. In that trial, patients were not …

… of erlotinib plus bevacizumab with erlotinib alone in patients … patients given bevacizumab
and erlotinib had improved progression-free survival compared with patients given erlotinib …

… This multicenter, randomized, phase III study investigated the efficacy of figitumumab plus
erlotinib compared with erlotinib alone in patients with pretreated, nonsmall-cell lung cancer (…

… by RECIST 1.0 in the erlotinib plus fulvestrant arm versus erlotinib alone arm. Secondary …
identification of patient subgroups that are distinct with respect to response. Patients were …

… With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR
… combination of erlotinib and bevacizumab compared with erlotinib alone in patients with non…

… (PFS) in patients with NSCLC with activating EGFR mutation compared with E alone. Overall
… We conducted survival follow-up of the patients in JO25567. Methods: JO25567 was open-…

… Phase III trials with erlotinib in non-small cell lung cancer and … to optimize the use of erlotinib
alone and in combination with … The two studies of erlotinib in patients with advanced solid …

… to erlotinib in patients with relapsed NSCLC. Although PFS was improved with the combination
compared with erlotinib alone (… , and RET, with erlotinib in patients with relapsed NSCLC …

… with erlotinib compared with erlotinib alone, as second- or third-line treatment, in patients …
Approximately 490 patients (245 per treatment arm) will receive erlotinib (150 mg oral daily) …

… of erlotinib alone or in combination with chemotherapy in patients with these characteristics.
… We thus developed a randomized phase II trial to investigate the efficacy of erlotinib alone …